Andrea P Moy1, Mark C Mochel1,2, Alona Muzikansky3, Lyn M Duncan1, Stefan Kraft1. 1. Pathology Service, Massachusetts General Hospital, Boston, Massachusetts. 2. Department of Pathology, Virginia Commonwealth University, Richmond, Virginia. 3. Biostatistics Center, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts.
Abstract
BACKGROUND: Sentinel lymph node (SLN) metastasis is a powerful predictor of survival in primary cutaneous melanoma. Lymphatic invasion (LI) may correlate with increased risk of SLN metastasis. Intralymphatic metastases, often difficult to detect on hematoxylin and eosin (H&E) stained sections, are readily identified with dual immunohistochemistry for melanocytic and lymphatic markers. METHODS: We used dual S100/D240 immunohistochemistry to detect LI in 125 melanomas from patients who underwent SLN biopsy and correlated LI with melanoma staging parameters and disease status. RESULTS: Dual immunohistochemistry allowed for the identification of LI in 33 cases (26%), compared to only 2% on H&E stained sections. Melanomas with LI showed greater thickness, higher mitotic rate and more frequent ulceration. Eleven of 33 cases with LI (33%) and 10 of 92 cases without LI (11%) were associated with a positive SLN (P = .006). More patients without LI were disease-free at last follow-up (80%) than patients with LI (50%; P = .002); LI was significantly associated with decreased progression-free survival. CONCLUSION: The detection of LI is improved by dual immunohistochemistry and predicts SLN metastasis. The presence of LI may impact therapeutic planning in melanoma, such as the decision to perform a SLN biopsy.
BACKGROUND: Sentinel lymph node (SLN) metastasis is a powerful predictor of survival in primary cutaneous melanoma. Lymphatic invasion (LI) may correlate with increased risk of SLN metastasis. Intralymphatic metastases, often difficult to detect on hematoxylin and eosin (H&E) stained sections, are readily identified with dual immunohistochemistry for melanocytic and lymphatic markers. METHODS: We used dual S100/D240 immunohistochemistry to detect LI in 125 melanomas from patients who underwent SLN biopsy and correlated LI with melanoma staging parameters and disease status. RESULTS: Dual immunohistochemistry allowed for the identification of LI in 33 cases (26%), compared to only 2% on H&E stained sections. Melanomas with LI showed greater thickness, higher mitotic rate and more frequent ulceration. Eleven of 33 cases with LI (33%) and 10 of 92 cases without LI (11%) were associated with a positive SLN (P = .006). More patients without LI were disease-free at last follow-up (80%) than patients with LI (50%; P = .002); LI was significantly associated with decreased progression-free survival. CONCLUSION: The detection of LI is improved by dual immunohistochemistry and predicts SLN metastasis. The presence of LI may impact therapeutic planning in melanoma, such as the decision to perform a SLN biopsy.
Authors: N A Ipenburg; O E Nieweg; T Ahmed; R van Doorn; R A Scolyer; G V Long; J F Thompson; S Lo Journal: Br J Surg Date: 2019-07-16 Impact factor: 6.939
Authors: Costanza Chiapponi; Hakan Alakus; Matthias Schmidt; Michael Faust; Christiane J Bruns; Reinhard Büttner; Marie-Lisa Eich; Anne M Schultheis Journal: Front Med (Lausanne) Date: 2022-02-21
Authors: Wen Ling Choong; Andrew Evans; Colin A Purdie; Huan Wang; Peter T Donnan; Brooke Lawson; E Jane Macaskill Journal: Br J Radiol Date: 2020-01-28 Impact factor: 3.039
Authors: Richard J Straker; Laura A Taylor; Madalyn G Neuwirth; Andrew J Sinnamon; Adrienne B Shannon; James Abbott; John T Miura; Emily Y Chu; Xiaowei Xu; Giorgos C Karakousis Journal: Am J Dermatopathol Date: 2022-01-01 Impact factor: 1.319